Cyhoeddiad
2024
- O’Hara, J. T. et al. 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150(11), pp. 1002-1011. (10.1001/jamaoto.2024.3371)
- Othman, J. et al. 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144(7), pp. 714-728. (10.1182/blood.2024024310)
- Othman, J. et al. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19), pp. 1931-1936. (10.1182/blood.2023023096)
- Russell, N. H. et al. 2024. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations. Journal of Clinical Oncology 42(10), pp. 1158-1168. (10.1200/JCO.23.00943)
2023
- Russell, N. et al. 2023. P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial. HemaSphere 7(S3), article number: e13145db. (10.1097/01.HS9.0000968844.13145.db)
- Othman, J. et al. 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7(16), pp. 4539-4549. (10.1182/bloodadvances.2023010276)
2022
- Russell, N. H. et al. 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140(S1), pp. 526-528. (10.1182/blood-2022-162377)
- Othman, J. et al. 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition, New Orleans, Louisiana, 10-13 December 2022, Vol. 140. Vol. S1. American Society of Hematology pp. 1036-1038., (10.1182/blood-2022-159433)
2021
- Mukherjee, S. et al. 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153, pp. 153-161. (10.1016/j.ejca.2021.05.020)
2017
- Mukherjee, S. et al. 2017. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer 74, pp. 38-46. (10.1016/j.ejca.2016.11.031)
2016
- Canham, J. 2016. The development of an intervention to support job retention and return to work for individuals with a diagnosis of bipolar disorder. PhD Thesis, Cardiff University.
2015
- Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
- Mukherjee, S. et al. 2015. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer 15(1), article number: 48. (10.1186/s12885-015-1062-y)
2013
- Cohen, D., Rees, S., Palmer, P., Allen, J., Howells, S., Greene, G. and Rhydderch, M. 2013. Factors that impact on medical student wellbeing: perspectives of risks. Project Report. [Online]. Gneral Medical Council. Available at: https://www.gmc-uk.org/about/what-we-do-and-why/data-and-research/research-and-insight-archive/factors-that-impact-on-medical-student-wellbeing
2012
- Cohen, D. A., Khan, S., Allen, J. and Sparrow, N. 2012. Shifting attitudes: the National Education Programme for work and health. Occupational Medicine 62(5), pp. 371-374. (10.1093/occmed/kqs081)
- Cohen, D. A., Allen, J., Rhydderch, S. M. and Aylward, M. 2012. The return to work discussion: A qualitative study of the line manager conversation about return to work and the development of an educational programme. Journal of Rehabilitation Medicine 44(8), pp. 677-683. (10.2340/16501977-0996)
Cynadleddau
- Othman, J. et al. 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition, New Orleans, Louisiana, 10-13 December 2022, Vol. 140. Vol. S1. American Society of Hematology pp. 1036-1038., (10.1182/blood-2022-159433)
Erthyglau
- O’Hara, J. T. et al. 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150(11), pp. 1002-1011. (10.1001/jamaoto.2024.3371)
- Othman, J. et al. 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144(7), pp. 714-728. (10.1182/blood.2024024310)
- Othman, J. et al. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19), pp. 1931-1936. (10.1182/blood.2023023096)
- Russell, N. H. et al. 2024. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed aml and overall survival in patients with npm1 and flt3 mutations. Journal of Clinical Oncology 42(10), pp. 1158-1168. (10.1200/JCO.23.00943)
- Russell, N. et al. 2023. P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial. HemaSphere 7(S3), article number: e13145db. (10.1097/01.HS9.0000968844.13145.db)
- Othman, J. et al. 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7(16), pp. 4539-4549. (10.1182/bloodadvances.2023010276)
- Russell, N. H. et al. 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140(S1), pp. 526-528. (10.1182/blood-2022-162377)
- Mukherjee, S. et al. 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153, pp. 153-161. (10.1016/j.ejca.2021.05.020)
- Mukherjee, S. et al. 2017. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer 74, pp. 38-46. (10.1016/j.ejca.2016.11.031)
- Noble, S. I. et al. 2015. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment 19(83), pp. 1-94. (10.3310/hta19830)
- Mukherjee, S. et al. 2015. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer 15(1), article number: 48. (10.1186/s12885-015-1062-y)
- Cohen, D. A., Khan, S., Allen, J. and Sparrow, N. 2012. Shifting attitudes: the National Education Programme for work and health. Occupational Medicine 62(5), pp. 371-374. (10.1093/occmed/kqs081)
- Cohen, D. A., Allen, J., Rhydderch, S. M. and Aylward, M. 2012. The return to work discussion: A qualitative study of the line manager conversation about return to work and the development of an educational programme. Journal of Rehabilitation Medicine 44(8), pp. 677-683. (10.2340/16501977-0996)
Gosodiad
- Canham, J. 2016. The development of an intervention to support job retention and return to work for individuals with a diagnosis of bipolar disorder. PhD Thesis, Cardiff University.
Monograffau
- Cohen, D., Rees, S., Palmer, P., Allen, J., Howells, S., Greene, G. and Rhydderch, M. 2013. Factors that impact on medical student wellbeing: perspectives of risks. Project Report. [Online]. Gneral Medical Council. Available at: https://www.gmc-uk.org/about/what-we-do-and-why/data-and-research/research-and-insight-archive/factors-that-impact-on-medical-student-wellbeing